Invesaro

Stocks Comparison

Chemours vs Innospec: revenue, profit, margins and growth compared

Chemours brought in $5.8B of revenue in fiscal 2025, Innospec $1.8B in fiscal 2025. Revenue changed by +0.4% at Chemours and -3.7% at Innospec on the year before, so Chemours grew faster. Chemours kept -6.6% of its revenue as net profit, Innospec 6.6%. Free cash flow was $51M at Chemours and $88M at Innospec.

Open the CC pageOpen the IOSP page

Side by side, latest fiscal year

CCIOSP
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$5.8B$1.8B
Revenue growth+0.4%-3.7%
Net income-$386M$116.6M
Net margin-6.6%6.6%
Free cash flow$51M$88M
Free cash flow margin0.9%4.9%
Earnings per share (diluted)-$2.57$4.67
Cash$670M$292.5M
Debt$4.1Bn/a
Price to earningsn/a21.1
Market value$2.2B$2.4B
Dividend yield3.54%1.73%
Rank by revenue in sector#109 of 451 · Industrials#231 of 451 · Industrials

Over the years

Revenue
CC FY2018: $6.6BCC FY2019: $5.5BCC FY2020: $5BCC FY2021: $6.3BCC FY2022: $6.8BCC FY2023: $6.1BCC FY2024: $5.8BCC FY2025: $5.8BIOSP FY2018: $1.5BIOSP FY2019: $1.5BIOSP FY2020: $1.2BIOSP FY2021: $1.5BIOSP FY2022: $2BIOSP FY2023: $1.9BIOSP FY2024: $1.8BIOSP FY2025: $1.8BFY18FY19FY20FY21FY22FY23FY24FY25
CC $5.8BIOSP $1.8B
Net income
CC FY2018: $995MCC FY2019: -$52MCC FY2020: $219MCC FY2021: $608MCC FY2022: $578MCC FY2023: -$253MCC FY2024: $69MCC FY2025: -$386MIOSP FY2018: $85MIOSP FY2019: $112.2MIOSP FY2020: $28.7MIOSP FY2021: $93.1MIOSP FY2022: $133MIOSP FY2023: $139.1MIOSP FY2024: $35.6MIOSP FY2025: $116.6MFY18FY19FY20FY21FY22FY23FY24FY25
CC -$386MIOSP $116.6M
Net margin
CC FY2018: 15.0%CC FY2019: -0.9%CC FY2020: 4.4%CC FY2021: 9.6%CC FY2022: 8.5%CC FY2023: -4.2%CC FY2024: 1.2%CC FY2025: -6.6%IOSP FY2018: 5.8%IOSP FY2019: 7.4%IOSP FY2020: 2.4%IOSP FY2021: 6.3%IOSP FY2022: 6.8%IOSP FY2023: 7.1%IOSP FY2024: 1.9%IOSP FY2025: 6.6%FY18FY19FY20FY21FY22FY23FY24FY25
CC -6.6%IOSP 6.6%
Revenue growth
CC FY2019: -16.8%CC FY2020: -10.1%CC FY2021: +27.7%CC FY2022: +7.7%CC FY2023: -11.0%CC FY2024: -4.9%CC FY2025: +0.4%IOSP FY2019: +2.5%IOSP FY2020: -21.2%IOSP FY2021: +24.3%IOSP FY2022: +32.4%IOSP FY2023: -0.8%IOSP FY2024: -5.3%IOSP FY2025: -3.7%FY19FY20FY21FY22FY23FY24FY25
CC +0.4%IOSP -3.7%
Free cash flow
CC FY2018: $642MCC FY2019: $169MCC FY2020: $540MCC FY2021: $537MCC FY2022: $448MCC FY2023: $186MCC FY2024: -$993MCC FY2025: $51MIOSP FY2018: $76MIOSP FY2019: $131.7MIOSP FY2020: $116.2MIOSP FY2021: $54.1MIOSP FY2022: $42.1MIOSP FY2023: $145.2MIOSP FY2024: $143.1MIOSP FY2025: $88MFY18FY19FY20FY21FY22FY23FY24FY25
CC $51MIOSP $88M

Fiscal years as each company reports them; the two may end in different months.

Questions about Chemours and Innospec

Which is bigger by revenue, Chemours or Innospec?

Chemours is bigger by revenue: $5.8B in fiscal 2025, against $1.8B for Innospec in fiscal 2025.

Which keeps more of its revenue as profit, Chemours or Innospec?

Chemours had a net margin of -6.6% in fiscal 2025; Innospec had 6.6% in fiscal 2025.

Which grew revenue faster, Chemours or Innospec?

In their latest fiscal years revenue changed by +0.4% at Chemours and -3.7% at Innospec.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

CC vs OLN
CC vs HUN
CC vs SOLS
CC vs FMC
IOSP vs OLN
HUN vs IOSP
IOSP vs SOLS

Compare more companies